Anti-Infectives World Market 2nd Edition Vol III Antivirals

Chapter One: Executive Summary

Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors
Chapter Two: Introduction


Introduction to Viruses
Examples of Pathogenic Viruses
Virus Function and Life History
Replication in DNA Viruses
Replication of RNA Viruses
Replication in Retroviruses


Host Defenses Against Viruses
Viral Ploys to Invade Host Cells and Circumvent Host Responses
Invasion of Host Cells
Subversion of the Immune Response
Avoidance of Immune Detection and Attack by Killer Cells


HIV and AIDS
Demographics and Statistics
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors


Overview
Description of Products
Nucleoside Reverse Transcriptase Inhibitors
Abacavir (Ziagen, GlaxoSmithKline)
Didanosine (Videx, Bristol-Myers Squibb)
Entecavir (Baraclude, Bristol-Myers Squibb)
Lamividine (Epivir, GlaxoSmithKline; Zeffix, GlaxoSmithKline)
Stavudine (Zerit, Bristol-Myers Squibb)
Telbivudine (Tyzeka, Novartis/Idenix Pharmaceuticals)
Zalcitabine (Hivid, Roche)


Zidovudine (Retrovir, GlaxoSmithKline)
Combination Nucleoside Reverse Transcriptase Inhibitors
Abacavir and Lamivudine (Epzicom/Kivexa, GlaxoSmithKline)
Abacavir sulfate, Lamivudine and Zidovudine (Trizivir, GlaxoSmithKline)
Lamivudine and Zidovudine (Combivir, GlaxoSmithKline)


Nucleotide Analogue Reverse Transcriptase Inhibitors
Adefovir dipivoxil (Hepsera, Gilead Sciences)
Tenofovir (Viread, Gilead Sciences)


Non-Nucleoside Reverse Transcriptase Inhibitors
Efavirenz (Sustiva, Bristol-Myers Squibb Oncology)
Delavirdine mesylate (Rescriptor, Agouron Pharmaceuticals)
Emtricitabine (Emtriva, Gilead Sciences)
Nevirapine (Viramune, Boehringer Ingelheim)


Combination Non-Nucleoside Reverse Transcriptase Inhibitors
Efavirenz/emtricitaine tenofovir disoproxil fumarate (Atripla, Bristol-Myers Squibb/Gilead Sciences)
Tenofovir and emtricitabine (Truvada, Gilead Sciences)


DNA Polymerase Inhibitors
Acyclovir (Zovirax, GlaxoSmithKline)
Cidofovir (Vistide, Gilead Sciences)
Famciclovir (Famvir, Novartis)
Foscarnet (Foscavir, AstraZeneca)
Ganciclovir (Cytovene, Roche)
Penciclovir (Denavir, Novartis)
Ribavirin (Virazole, ICN Pharmaceuticals)
Telbivudine (Tyzeka, Idenix/Novartis)
Valacyclovir (Valtrex, GlaxoSmithKline)
Valganciclovir (Valcyte, Hoffman-LaRoche)


Generic Drug Impact and Availability
Research and Development
Market Size and Growth
Competitive Analysis
Chapter Four: Protease Inhibitors


Overview
Description of Products
Protease Inhibitors
Amprenavir (Agenerase, GlaxoSmithKline)
Atazanavir (Reyataz, Bristol-Myers Squibb)
Darunavir (Prezista, Tibotec Pharmaceuticals)
Fosamprenavir (Lexiva, Vertex and GlaxoSmithKline)
Indinavir (Crixivan, Merck)
Nelfinavir (Viracept, Agouron Pharmaceuticals)
Ritonavir (Norvir, Abbott Laboratories)
Saquinavir (Fortovase, Roche; Invirase, Roche)
Tripanavir (Aptivus, Boehringer Ingelheim)
Combination Protease Inhibitors
Lopinavir and Ritonavir (Kaletra, Abbott Laboratories)


Research and Development
Market Size and Growth
Competitive Analysis
Chapter Five: Other Antivirals


Overview
Description of Products
Immune Response Modifiers
Imiquimod (Aldara, 3M Pharmaceuticals)


Immunoglobulin G
Cytomegalovirus immune globulin (CytoGam, MedImmune)


Adamantane Derivatives
Rimantadine HCl (Flumadine, Forest Laboratories)
Amantadine (Symmetrel, Endo Laboratories)


Fusion Inhibitors
Enfuvirtide (Fuzeon, Trimeris/Roche)


Interferons
Interferon alfacon-1 (Infergen, Amgen)
Interferon alpha 2a (Pegasys, Roche)
Interferon Alfa-n3 (Alpheron N, Hemispherx Biopharma)
Ribavirin + Interferon Alfa 2-a (Pegasys + Copegus, Roche)
Ribavirin (Rebetol, Schering-Plough; Rebetron, Schering-Plough; Ribasphere, Three Rivers Pharmaceuticals)


Neuraminidase Inhibitors
Zanamivir (Relenza, GlaxoSmithKline)
Oseltamivir phosphate (Tamiflu, Roche)


Immunizing Agents
Hepatitis B immune globulin injection (HepaGam B (Cangene)
Respiratory syncytial virus immune globulin (RespiGam, MedImmune)


Monoclonal Antibodies
Palivizumab (Synagis, MedImmune)


Miscellaneous Antivirals
Molixan, (Novelos Therapeutics/Pharma BAM)


Generic Drug Impact and Availability
Research and Development
Attachment and Fusion Inhibitors
Gene Therapies
Integrase Inhibitors
Maturation Inhibitors
Neuraminidase Inhibitors
Zinc Finger Inhibitors
Antisense Drugs
Cytokines
Monoclonal Antibodies
Other


Market Size and Growth
Competitive Analysis
Chapter Six: Issues and Trends Affecting the Antiviral Market


Introduction
Antiviral Drug Resistance
Medicare Part D
HIV Drug Cost Controversy
Antiretroviral treatment regimens
HIV and Women
Global Surveillance
Maturation Inhibitor Development
Biochemical Prevention and Treatment of Viral Infections
COSTS AND Funding of HIV Treatment
Access to HIV/AIDS Treatment
Chapter Seven: Antiviral Drugs: Total Market Size and Forecast


Overview
Total Market Size and Forecast
chapter Eight: Corporate Profiles


Introduction
Abbott Laboratories
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
GlaxoSmithKline
MedImmune, Inc.
Merck & Company, Inc.
Novartis Pharmaceuticals Corporation
Roche
Schering-Plough Corporation
APPENDIX: Company Names and Addresses



Table of exhibits



Chapter One: Executive Summary


Table 1-1:The World Market for Antiviral Drugs 2004-2011
Chapter Two: Introduction


Table 2-1: Host Cell Receptors
Table 2-2: Estimated World and U.S. Incidence of Viral Infections
Figure 2-1: Estimated World and U.S. Incidence of Leading Viral Infections
Table 2-3: World Population by Selected Geographical Region, 2006-2050
Figure 2-2: World Population by Selected Geographuhhical Region, 2006-2050
Table 2-4: Estimated World Population by Age and Geographical Region, 2006
Table 2-3: Estimated World Population by Age and Geographical Region, 2006
Chapter Three: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors


Table 3-1: Currently Available Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 3-2: Currently Available Combination Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 3-3: Currently Available Nucleotide Analog Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 3-4: Currently Available Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 3-5: Currently Available Combination Non-Nucleoside Reverse Transcriptase Inhibitors (Type, Brand, and Manufacturer)
Table 3-6: Currently Available DNA Polymerase Inhibitors (Type, Brand, and Manufacturer)
Table 3-7: New Generic Drug Approvals for Nucleoside Analogs, Transcriptase Inhibitors, and DNA Polymerase Inhibitors, United States, 2005-2006
Table 3-8: Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors In Development
Table 3-9: The Market for Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitor 2004-2011
Figure 3-1: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market 2004-2011
Table 3-10: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Infection Type, 2006
Figure 3-2: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Infection Type, 2006
Table 3-11: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Products Sales by Geographic Region, 2006
Figure 3-3: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Market Share by Geographic Region, 2006
Table 3-12: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 3-4: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share by Leading Suppliers 2006
Table 3-13: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 3-5: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Projected Market Share by Leading Suppliers 2011
Table 3-14: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Sales of Top Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors 2006
Figure 3-6: Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor Market Estimated Market Share of Top Nucleoside Analog, Transcriptase Inhibitors and DNA Polymerase Inhibitor , 2006
Chapter Four: Protease Inhibitors


Table 4-1: Currently Available Protease Inhibitors (Type, Brand, and Manufacturer)
Table 4-2: Currently Available Combination Protease Inhibitors (Type, Brand, and Manufacturer)
Table 4-3: Protease Inhibitors in Development
Table 4-4: The Market for Protease Inhibitors 2004-2011
Figure 4-1: Protease Inhibitor Market 2004-2011
Table 4-5: Protease Inhibitor Market Estimated Products Sales by Geographic Region, 2006
Figure 4-2: Protease Inhibitor Market Market Share by Geographic Region, 2006
Table 4-6: Protease Inhibitor Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 4-3: Protease Inhibitor Market Estimated Market Share by Leading Suppliers 2006
Table 4-7: Protease Inhibitor Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 4-4: Protease Inhibitor Market Projected Market Share by Leading Suppliers 2011
Table 4-8: Protease Inhibitor Market Estimated Sales of Top Protease Inhibitors 2006
Figure 4-5: Protease Inhibitor Market Estimated Market Share of Top Protease
Inhibitors, 2006 Chapter Five: Other Antivirals


Table 5-1: Currently Available Antiviral Immune Response Modifiers (Type, Brand, and Manufacturer)
Table 5-2: Currently Available Immunoglobulin G Products (Type, Brand, and Manufacturer)
Table 5-3: Currently Available Adamantane Derivatives (Type, Brand, and Manufacturer)
Table 5-4: Currently Available Fusion Inhibitors (Type, Brand, and Manufacturer)
Table 5-5: Currently Available Interferons (Type, Brand, and Manufacturer)
Table 5-6: Currently Available Neuraminidase Inhibitors (Type, Brand, and Manufacturer)
Table 5-7: Currently Available Immunizing Agents (Type, Brand, and Manufacturer)
Table 5-8: Currently Available Monoclonal Antibodies (Type, Brand, and Manufacturer)
Table 5-9: Miscellaneous Antivirals (Type, Brand, and Manufacturer)
Table 5-10: New Generic Drug Approvals for Other Antivirals, United States, 2005-2006
Table 5-11: Other Antivirals in Development
Table 5-13: The Market for Other Antivirals 2004-2011
Figure 5-1: Other Antiviral Market 2004-2011
Table 5-14: Other Antiviral Market Estimated Products Sales by Infection Type, 2006
Figure 5-2: Other Antiviral Market Market Share by Infection Type, 2006
Table 5-15: Other Antiviral Market Estimated Products Sales by Geographic Region, 2006
Figure 5-3: Other Antiviral Market Market Share by Geographic Region, 2006
Table 5-16: Other Antiviral Market Estimated Revenues and Market Share of Leading Suppliers 2006
Figure 5-4: Other Antiviral Market Estimated Market Share by Leading Suppliers 2006
Table 5-17: Other Antiviral Market Projected Revenues and Market Share of Leading Suppliers 2011
Figure 5-5: Other Antiviral Market Projected Market Share by Leading Suppliers 2011
Table 5-18: Other Antiviral Market Estimated Sales of Other Antiviral Products 2006
Figure 5-6: Other Antiviral Market Estimated Market Share of Top Other Antiviral Products, 2006
Chapter Six: Issues and Trends Affecting the
Antiviral Market

Table 6-1 People Living with HIV/AIDS by Region
Table 6-2:AIDS Resource Needs (USS billion)
Table 6-3: Access Needs of Adults and Children with HIV by Regions
Table 6-4: Antiretroviral Access for HIV Infected Individuals by Region
Chapter Seven: Antiviral Drugs: Total Market Size and Forecast


Table 7-1: The World Market for Antiviral Drugs 2004-2011 Compound Annual Growth Rate
Figure 7-1: The World Market for Antiviral Drugs 2004-2011
Table 7-2: Antiviral Drug Market by Type 2004-2011
Figure 7-2: The World Market for Antiviral Drugs Revenues by Type 2004-2011
Figure 7-3: The World Market for Antiviral Drugs Revenues by Type 2006 and 2011